Skip to main content

Table 5 Tumour characteristics of HCC cases according to TNF-ɑ polymorphism

From: Association of IL-10 and TNF-α polymorphisms with risk and aggressiveness of hepatocellular carcinoma in patients with HCV-related cirrhosis

   Genotype Test of significance
  Total, n = 73(%) GG GA AA
Portal vein
 Thrombosed 10 10 (28.6) 0 (0.0) 0 (0.0) MC
P = 0.002*
 Patent 63 25 (71.4) 22 (100.0) 16 (100.0)
Spleen
 Splenectomy 2 0 (0.0) 2 (9.1) 0(0.0) MC
P = 0.313
 Mild 26 14 (40.0) 8 (36.4) 4(25.0)
 Moderate 39 18 (51.4) 12 (54.5) 9(56.2)
 Marked 6 2 (5.7) 2 (9.1) 2(12.5)
Ascites
 Negative 62 26 (74.3) 22 (100.0) 14 (87.5) MC
P = 0.029*
 Positive 11 9 (25.7) 0 (0.0) 2 (12.5)
Lymph node
 Negative 64 28 (80.0) 22 (100.0) 14 (87.5) MC
P = 0.08
 Positive 9 7 (20.0) 0 (0.0) 2 (12.5)
BCLC
 A 11 0 (0.0) 5 (22.7) 6 (37.5) MC
P < 0.001*
 B 24 2 (5.7) 15 (68.2) 7 (43.8)
 C 24 19 (54.3) 2 (9.1) 3 (18.8)
 D 14 14 (40.0) 0 (0.00) 0 (0.0)
Site of lesion
 Right lobe 25 12 (34.3) 9 (40.9) 4 (25.0) MC
P = 0.74
 Left lobe 12 7 (20.0) 2 (9.1) 3 (18.8)
 Multifocal 36 16 (45.7) 11 (50.0) 9 (56.2)
AGI
 A 22 0 (0.0) 12 (54.5) 10 (62.5) MC
P < 0.001*
 B 23 9 (25.7) 8 (36.4) 6 (37.5)
 C 28 26 (74.3) 2 (9.1) 0 (0.0)
  1. * means statistically significant